So on one side journalists lament lack of new drug development & just the shoddy state of healthcare tech, while as soon as any new data that can potentially unlock new drug targets (23andMe) or provider better support (Google DeepMind Health) is introduced, Such efforts are quickly demonized with spread of Fear, Uncertainty and Doubt. Rather than asking important questions such as at which level the "aggregate" data…
About what?
Privacy?
The blog entry is focused on monetization, not privacy.
23 also has a deal with Pfizer.
And they have hired people, e.g., from Genentech, that will help them try some drug discovery research themselves.
But does anyone outside the company seriously believe this is going to lead to anything? They are not a therapeutics company.
They are a data broker.
Why not just submit DNA samples directly to a drug company instead of a data broker?
The only thing we can call "shoddy" here is 23andme's original business model: selling genetic test results. The question some are asking is whether they knew that when they started.
With the collected data, they now have value. There will be buyers.
Whether that value is ever passed on to patients is less certain.